(Margetuximab)Biosimilar-Reference-Antibody-GS40420 新品

货号：GS40420

Margetuximab is an Fc-engineered, humanized monoclonal antibody that targets human epidermal growth factor receptor 2 (HER2). Its Fc region is modified to enhance binding to both the high-affinity (CD16A-158V) and low-affinity (CD16A-158F) variants of the Fcγ receptor CD16A on natural killer (NK) cells and macrophages. This engineering aims to improve antibody-dependent cellular cytotoxicity (ADCC) compared to the unmodified anti-HER2 antibody trastuzumab. By binding to HER2, it inhibits downstream proliferative signaling and promotes immune-mediated tumor cell killing. It is approved in combination with chemotherapy for the treatment of adults with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.